psychopharmacology | CARLAT PUBLISHING

Psychopharm Commandment #10: Don’t Fear these Meds

May 29, 2023

Kellie Newsome, PMHNP and Chris Aiken, MD

Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

Psychopharm Commandments 8B: Unwise Combinations

May 8, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

These are the medications you don’t want to combine.

Psychopharm Commandment 7A: Red Flags & Controlled Meds

April 3, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

The DEA has warned pharmacists to watch for Red Flags in controlled prescriptions, and we’ll show you what they are and how to use them therapeutically in practice.

The Other Side of Psych Meds: An Interview with David Healy

March 6, 2023

Chris Aiken, MD

Find out what psychiatry's favorite critic does in his practice.

Ketamine Comes Home

February 26, 2023

Kellie Newsome, PMHNP and Chris Aiken, MD

Online clinics delivered at-home ketamine throughout the pandemic, and we’re just becoming aware of the consequences.

Psychopharm Commandment 3: Lithium Toxicity

October 10, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Lithium toxicity: How to avoid it, and what to do when it happens.

CLINICAL UPDATE

Six Tips From Prescribing Psychotropics

August 1, 2022

Chris Aiken, MD

Chris Aiken, MD.

Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

New answers to age-old questions, such as adjusting the dose to account for drug interactions, reducing side effects, maintaining weight, and protecting that finicky organ—the kidneys.

What Gets in the Way of Antidepressants?

August 1, 2022

Chris Aiken, MD and Garrett Rossi, MD.

Garrett Rossi, MD.
Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

Chris Aiken, MD.
Editor-in-Chief, The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Rossi and Dr. Aiken, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Recent research has added to our understanding of factors that inhibit response to treatment, including major stress, nonadherence, and anxiety.

Paul Riordan, MD. Assistant Consulting Professor of Psychiatry, Duke University. Dr. Riordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

It is the best of drugs; it is the worst of drugs. Quetiapine (Seroquel) has a few benefits that are unmatched by other medications, and here we explore where it fits in depression, bipolar, schizophrenia, as well as off-label uses like anxiety and sleep.

Real-World Alcohol Use Disorder Treatment

March 1, 2022

Ismene Petrakis, MD

Ismene Petrakis, MD

Addiction psychiatrist and professor at Yale School of Medicine. Chief of Mental Health, VA Connecticut Healthcare System, New Haven, CT.

Dr. Petrakis has disclosed that she participated in a study in which she did not receive any compensation from Alkermes apart from medication and Alkermes did not fund the study. Dr. Capurso has reviewed this material and found no evidence of bias pertaining to this educational activity.

Many patient with alcohol use disorder (AUD) also have comorbid psychiatric illness. Treating these patients can be challenging however there are evidenced based approaches that have been shown to be effective. Dr. Petrakis reviews the latest evidence in treating AUD in this challenging population.